Table 1 Association of NFE2L2 mRNA expression with clinicopathologic features

A

n

Mean (+/− SD)

P

Age

< median age (61.79 years)

971

9.13 (0.56)

<0.001

≥ median age (61.79 years)

971

9.04 (0.60)

Size

T1

842

9.10 (0.59)

0.200

T2/3/4

1082

9.07 (0.57)

n.a.

18

LN

negative

1007

9.07 (0.59)

0.213

positive

929

9.10 (0.58)

n.a.

6

Tumour grade

I

163

9.18 (0.57)

0.021

II

767

9.09 (0.57)

III

947

9.07 (0.58)

n.a.

65

Histology

invasive lobular

147

9.09 (0.65)

0.001

invasive ductal

1548

9.06 (0.58)

special differentiation

148

9.22 (0.54)

lobular and ductal mixed forms

90

9.22 (0.58)

only “invasive tumour” as information

9

9.27 (0.33)

MP

premenopausal

428

9.15 (0.54)

0.003

postmenopausal

1503

9.06 (0.59)

n.a.

11

HER2

score 0/+

667

9.11 (0.51)

0.041

score ++/+++

147

9.19 (0.50)

n.a.

1128

ER

neg

432

9.07 (0.58)

0.981

pos

1482

9.09 (0.58)

B

n

Mean (+/− SD)

P

Age

< median age (60.2 years)

88

−0.71 (0.32)

0.519

≥ median age (60.2 years)

88

−0.69 (0.37)

Size

T1

68

−0.63 (0.28)

0.045

T2/3/4

108

−0.74 (0.38)

LN

negative

74

−0.70 (0.35)

0.389

positive

96

−0.71 (0.35)

n.a.

6

Tumour grade

I

27

−0.71 (0.31)

0.513

II

115

−0.69 (0.34)

III

32

−0.74 (0.40)

n.a.

2

Histology

invasive lobular carcinoma

22

−0.69 (0.47)

0.346

invasive ductal carcinoma

135

−0.68 (0.30)

ductal carcinoma with specific differentiation

19

−0.83 (0.48)

MP

premenopausal

48

−0.69 (0.29)

0.873

postmenopausal

128

−0.70 (0.37)

HER2

score 0/+

133

−0.72 (0.38)

0.798

score ++/+++

40

−0.66 (0.21)

n.a.

3

ER

neg

49

−0.75 (0.41)

0.215

pos

127

−0.68 (0.32)

PR

neg

59

−0.78 (0.42)

0.040

pos

117

−0.66 (0.29)